Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association, discusses pharmacists’ role in diabetes and CKD care at ASN Kidney Week 2026.
|Articles|November 9, 2021
Daily Medication Pearl: Dapagliflozin (Farxiga) for Type 2 Diabetes Mellitus
Author(s)Saro Arakelians, PharmD
By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose.
Advertisement
Medication Pearl of the Day: Dapagliflozin (Farxiga)
Indication: Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Insight:
- Dosing: The recommended starting dose is 5 mg once daily, taken in the morning, with or without food.
- Dosage form: Tablets 5 mg and 10 mg.
- Adverse events (AEs): The most common AEs associated with dapagliflozin(5% or greater incidence) were female genital mycotic infections, nasopharyngitis, and urinary tract infections.
- Mechanism of action: Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose, lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
- Manufacturer: AstraZeneca
Sources:
Advertisement
Related to this article
Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Community Pharmacists Guide Patients New to Glucose Monitoring
2
FDA Grants Accelerated Approval to First Plasmid DNA-Based Immunotherapy for Recurrent Respiratory Papillomatosis
3
Caitlin McClain, Peggy Lillis Foundation Board Member, Shares Her Experience With C difficile
4
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
5